var data={"title":"Silver sulfadiazine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Silver sulfadiazine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6953?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=silver-sulfadiazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Silver sulfadiazine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=silver-sulfadiazine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Silver sulfadiazine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221120\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Silvadene;</li>\n      <li>SSD;</li>\n      <li>Thermazene [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221121\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flamazine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221136\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221123\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Burn treatment:</b> Topical: Apply to a thickness of <sup>1</sup>/<sub>16</sub> inch once or twice daily; reapply as needed to areas where the cream is removed by patient activity as the burned area should be covered with cream at all times. Continue use until healing has occurred or the burn site is ready for grafting. Do not discontinue therapy if the possibility of infection exists unless a significant adverse reaction has occurred.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221132\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=silver-sulfadiazine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Silver sulfadiazine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Burn treatment:</b> Infants &ge;2 months, Children, and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221124\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46925169\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; drug accumulation may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46925170\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; drug accumulation may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221103\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Silvadene: 1% (20 g, 25 g, 50 g, 85 g, 400 g, 1000 g) [contains methylparaben, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SSD: 1% (25 g, 50 g, 85 g, 400 g) [contains cetyl alcohol, methylparaben, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thermazene: 1% (20 g [DSC], 50 g [DSC], 85 g [DSC], 400 g [DSC], 1000 g [DSC]) [contains methylparaben, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1% (20 g, 25 g, 50 g, 85 g, 400 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221089\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803229\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For topical use only; avoid contact with eyes. Apply with a sterile-gloved hand. Burned area should be covered with cream at all times; reapply to areas where cream has been removed by patient activity. Dressings may be used if necessary. Reapply immediately after hydrotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221104\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Burn treatment:</b> As an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221096\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, pruritus, skin discoloration, skin photosensitivity, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (may be related to sulfa component)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Interstitial nephritis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221108\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to silver sulfadiazine or any component of the formulation; pregnant women approaching or at term; premature infants or neonates &le;2 months of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221093\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Fungal proliferation may rarely occur in and below the eschar.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Systemic effects: Systemic absorption may be significant and adverse reactions may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; sulfadiazine may accumulate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; sulfadiazine may accumulate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For topical use only. Avoid contact with eyes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300042\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221097\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9890&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611621\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, silver sulfadiazine is contraindicated for use near term, on premature infants, or on newborn infants during the first 2 months of life (refer to Sulfadiazine monograph).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611623\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if silver sulfadiazine is found in breast milk following topical application; however, sulfonamide serum concentrations may reach therapeutic levels following application to extensive areas. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. Oral sulfadiazine is contraindicated in nursing mothers since sulfonamides cross into the milk and may cause kernicterus in the newborn (refer to Sulfadiazine monograph).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221101\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, urinalysis, renal function tests, CBC in patients with extensive burns on long-term treatment. Serum sulfa concentrations, if clinically indicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221092\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts upon the bacterial cell wall and cell membrane. Bactericidal for many gram-negative and gram-positive bacteria and is effective against yeast. Active against <i>Pseudomonas aeruginosa</i>, <i>Pseudomonas maltophilia</i>, <i>Enterobacter</i> species, <i>Klebsiella</i> species, <i>Serratia</i> species, <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Morganella morganii</i>, <i>Providencia rettgeri</i>, <i>Proteus vulgaris</i>, <i>Providencia</i> species, <i>Citrobacter</i> species, <i>Acinetobacter calcoaceticus</i>, <i>Staphylococcus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Enterococcus</i> species, <i>Candida albicans</i>, <i>Corynebacterium diphtheriae</i>, and <i>Clostridium perfringens</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221107\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Negligible (superficial and deep burns and normal skin); increased absorption with blister removal (Sano 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Sulfadiazine: ~24 hours (Sano 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Silver: Feces; slow excretion rate; Sulfadiazine: Urine (6.6% within 5 days) (Sano 1982)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221111\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Silvadene External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (50 g): $14.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Silver Sulfadiazine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (50 g): $15.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (SSD External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (50 g): $14.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221112\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldo-Silvederma (HK);</li>\n      <li>Argentafil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Argentamicina (PE);</li>\n      <li>Argenzil (UY);</li>\n      <li>Bactin (LK);</li>\n      <li>Bactrazine (ZW);</li>\n      <li>Burnazin (ID);</li>\n      <li>Burnsil (PH);</li>\n      <li>Burnzorb (PH);</li>\n      <li>Canflame (TW);</li>\n      <li>Dermazin (HK, HU, PL, RU, SI, SK, TH);</li>\n      <li>Falmmazine (VN);</li>\n      <li>Flamazine (AE, AU, BH, CY, DK, EG, FI, GB, IE, IQ, IR, IS, JO, KW, LB, LY, MT, NO, NZ, OM, PK, QA, SA, SY, TH, TW, YE, ZA);</li>\n      <li>Flammazine (AT, BE, BG, CH, DE, ES, FR, GR, LU, NL, PH, PT);</li>\n      <li>Flugen (TW);</li>\n      <li>No-Burn (JO);</li>\n      <li>Platsul-A (AR, CL);</li>\n      <li>Silbecor (ZW);</li>\n      <li>Silmazin (KR);</li>\n      <li>Silvadene (MX, TR, TW);</li>\n      <li>Silvadex (LK);</li>\n      <li>Silvadiazin (AE, KW);</li>\n      <li>Silvadin (EC);</li>\n      <li>Silvederma (ES, PH, VE);</li>\n      <li>Silverderm (TH);</li>\n      <li>Silverdiazina (PE);</li>\n      <li>Silverin (BH, JO, QA, SA);</li>\n      <li>Silverol (IL);</li>\n      <li>Silvex (HK, LK);</li>\n      <li>Silvirin (IN, VN);</li>\n      <li>Silzine (LK);</li>\n      <li>Sofargen (IT);</li>\n      <li>Sterizol (PH);</li>\n      <li>Sulfadiacina de Plata (PY);</li>\n      <li>Sulfaplata (CO, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Sulfargin (EE);</li>\n      <li>Synvodex (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/silver-sulfadiazine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulick MI, Wong R, Okarma TB, et al, &ldquo;Prospective Study of Side Effects Associated With the Use of Silver Sulfadiazine in Severely Burned Patients,&rdquo; <i>Ann Plast Surg</i>, 1985, 14(5):407-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/silver-sulfadiazine-drug-information/abstract-text/4083697/pubmed\" target=\"_blank\" id=\"4083697\">4083697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lockhart SP, Rushworth A, Azmy AA, et al, &ldquo;Topical Silver Sulfadiazine: Side Effects and Urinary Excretion,&rdquo; <i>Burns Incl Therm Inj</i>, 1983, 10(1):9-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/silver-sulfadiazine-drug-information/abstract-text/6640389/pubmed\" target=\"_blank\" id=\"6640389\">6640389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sano S, Fujimori R, Takashima M, Itokawa Y. Absorption, excretion and tissue distribution of silver sulphadiazine. <i>Burns Incl Therm Inj</i>. 1982;8:278-285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/silver-sulfadiazine-drug-information/abstract-text/7066727/pubmed\" target=\"_blank\" id=\"7066727\">7066727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silvadene (silver sulfadiazine) [prescribing information]. New York, NY: Pfizer; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SSD (silver sulfadiazine) [prescribing information]. Shreveport, LA: Dr. Reddy&rsquo;s Laboratories; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/silver-sulfadiazine-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9890 Version 132.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221120\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F221121\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221136\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221123\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F221132\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F221124\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46925169\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46925170\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221103\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F221089\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F803229\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F221104\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221096\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221108\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221093\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300042\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F221097\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9611621\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9611623\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F221101\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221092\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F221107\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F221111\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F221112\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9890|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=silver-sulfadiazine-patient-drug-information\" class=\"drug drug_patient\">Silver sulfadiazine: Patient drug information</a></li><li><a href=\"topic.htm?path=silver-sulfadiazine-pediatric-drug-information\" class=\"drug drug_pediatric\">Silver sulfadiazine: Pediatric drug information</a></li></ul></div></div>","javascript":null}